EN
The future of technological innovation.
Clinical Trials
  • TCR-T
    TCR-T
    TCR-T technology is a T cell immunotherapy technique that engineers patient’s autologous T cells to express tumor antigen-specific T cell receptors (TCRs). TCR-T therapy includes the identification of tumor-specific TCRs, the construction of TCR expression vectors, TCR-T cell manufacturing, and immune monitoring after TCR-T transfusion. Compared to CAR-T (chimeric antigen receptor T cell), TCR-T has a broader space for antigen selection, therefore it can not only be applied to a wider range of cancer types, but also reduces off-target effects. However, despite the success of TCR-T cells in preclinical testing and small-scale patient treatments, clinical trial data for TCR-T therapy is still limited. Presently, TCRCure is carrying out a proof-of-concept clinical trial to deliver TCR-T therapy for patients with HPV- and EBV-associated tumors. Cancers caused by HPV include cervical cancer and head and neck cancer. Cancers caused by EBV include nasopharyngeal carcinoma, B cell lymphoma, and gastric carcinoma. These cancers are characterized by high-risk, refractory features especially in the Chinese population and current first-line treatment programs are problematic due to their low efficiency, strong side effects, and recurrence. TCRCure’s TCR-T products are expected to solve these problems and provide new treatment options for patients. TCRCure’s proof-of-concept clinical study encompasses TCR-T design and TCR-T cell production, as well as the entire clinical program such as patient selection, safety assessment, and efficacy evaluation. The program in its entirety will help promote TCR-T technology for the treatment of cancers.
    TCR-T technology is a T cell immunotherapy technique that engineers patient’s autologous T cells to express tumor antigen-specific T cell receptors (TCRs). TCR-T therapy includes the identification of tumor-specific TCRs, the construction of TCR expression vectors, TCR-T cell manufacturing, and immune monitoring after TCR-T transfusion. Compared to CAR-T (chimeric antigen receptor T cell), TCR-T has a broader space for antigen selection, therefore it can not only be applied to a wider range of cancer types, but also reduces off-target effects. However, despite the success of TCR-T cells in preclinical testing and small-scale patient treatments, clinical trial data for TCR-T therapy is still limited.

    Presently, TCRCure is carrying out a proof-of-concept clinical trial to deliver TCR-T therapy for patients with HPV- and EBV-associated tumors. Cancers caused by HPV include cervical cancer and head and neck cancer.  Cancers caused by EBV include nasopharyngeal carcinoma, B cell lymphoma, and gastric carcinoma. These cancers are characterized by high-risk, refractory features especially in the Chinese population and current first-line treatment programs are problematic due to their low efficiency, strong side effects, and recurrence. TCRCure’s TCR-T products are expected to solve these problems and provide new treatment options for patients.
     
    TCRCure’s proof-of-concept clinical study encompasses TCR-T design and TCR-T cell production, as well as the entire clinical program such as patient selection, safety assessment, and efficacy evaluation. The program in its entirety will help promote TCR-T technology for the treatment of cancers.




    HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer


Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer
Introduction to TCRCure
Immune Cell Therapy
Product and Services
News
Recruitment

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer